How much funding has Apellis raised?

Apellis has raised $490.1M in total funding, most recently a Corporate Round.

Who are Apellis's investors?

Apellis's investors include Unknown Ventures, AJU IB Investment, Morningside Group, Cormorant Asset Management, Hillhouse Capital, Epidarex Capital.

Where is Apellis headquartered?

Apellis is headquartered in Waltham, Massachusetts, United States.

How many employees does Apellis have?

Apellis has 501-1000 employees.

Apellis

IPO

Courageous Science + Compassion

Public · Waltham, United States · Founded 2009 · $490.1M raised

Biotech

Headquarters: Waltham, Massachusetts
Employees: 501–1000
Founded: 2009
Business Model: B2B
Website: apellis.com

Total Funding: $490.1M
Last Round: $350.0M Corporate RoundFeb 2023
Rounds: 4
Type: Public

About

Apellis Pharmaceuticals (Nasdaq: APLS) is a clinical-stage and commercial-stage biopharmaceutical company focused on the complement system, a key branch of innate immunity. Founded in 2009 by Cedric Francois and Dinesh Bhatt, the company pioneered targeted C3 inhibition with its lead compound pegcetacoplan. Apellis received FDA approval for EMPAVELI for paroxysmal nocturnal hemoglobinuria (PNH) in 2021 and SYFOVRE for geographic atrophy (GA) in 2023 — the first approved treatment for GA. Headquartered in Waltham, Massachusetts.

Summary

Apellis is a Biotech company based in Waltham, United States, founded in 2009. It has raised $490.1M in total across 4 rounds, most recently a $350.0M Corporate Round round in Feb 2023. Investors include Unknown Ventures, AJU IB Investment and Morningside Group.

LinkedIn X (Twitter)